Study details
Enrolling now
MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder
Stephen Robert Marder
NCT IDNCT05790239ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 1.1 years
Ages
18+
Locations
2 sites in CA
About this study
Researchers are testing whether MDMA-assisted therapy, combined with psychotherapy, is more effective than low dose d-amphetamine-assisted therapy at reducing PTSD symptoms in veterans. The trial will last 395 days and involve approximately 40 participants aged 18 or older who have moderate to severe PTSD.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Therapy
- 2.Take 3,4-methylenedioxymethamphetamine
- 3.Take d-amphetamine
PhasePhase 2
Drugd-amphetamine
Primary goalCompare changes in PTSD symptom severity in the MDMA vs active control group
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
dexamfetamine
Endpoints
Primary: Compare changes in PTSD symptom severity in the MDMA vs active control group.
Body systems
Psychiatry / Mental Health